JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Voorman, R. L.
Right arrow Articles by Wang, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Voorman, R. L.
Right arrow Articles by Wang, X.

Vol. 287, Issue 1, 381-388, October 1998

Microsomal Metabolism of Delavirdine: Evidence for Mechanism-Based Inactivation of Human Cytochrome P450 3A1

Richard L. Voorman, Stephen M. Maio, N. Ann Payne, Zhiyang Zhao, Kenneth A. Koeplinger and Xiaohong Wang

Drug Metabolism and Disposition Research, Pharmacia and Upjohn, Kalamazoo, Michigan

Administration of delavirdine, an HIV-1 reverse transcriptase inhibitor, to rats or monkeys resulted in apparent loss of hepatic microsomal CYP3A and delavirdine desalkylation activity. Human CYP3A catalyzes the formation of desalkyl delavirdine and 6'-hydroxy delavirdine, an unstable metabolite, while CYP2D6 catalyzes only desalkyl delavirdine. CYP2D6 catalyzed desalkyl delavirdine formation was linear with time (up to 30 min) but when catalyzed by cDNA expressed CYP3A4 or human liver microsomes the reaction rate declined progressively with time. Coincubation with triazolam showed that delavirdine caused a time- and NADPH-dependent loss of CYP3A4 activity in human liver microsomes as measured by triazolam 1'-hydroxylation. The catalytic activity loss was saturable and was characterized by a Ki of 21.6 ± 8.9 µM and a kinact of 0.59 ± 0.08 min-1. An apparent partition ratio of 41 was determined with cDNA expressed CYP3A4, based on the substrate depletion method. Incubation of [14C]delavirdine with microsomes from several species resulted in irreversible association with an approximately 50 kDa protein, as demonstrated by SDS-PAGE/autoradiography. Binding to the protein was NADPH dependent, glutathione insensitive, proportional to the level of CYP3A expression and was inhibited by ketoconazole, a specific CYP3A inhibitor. NADPH-dependent irreversible binding to human and rat total microsomal protein was demonstrated following exhaustive extraction of microsomal protein. Binding was decreased in the presence of glutathione and appeared to be related to expression level of CYP3A. These results suggest that delavirdine can inactivate CYP3A and has the potential to slow the metabolism of coadministered CYP3A substrates.

0022-3565/98/2871-0381$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
H.-K. Lim, N. Duczak Jr., L. Brougham, M. Elliot, K. Patel, and K. Chan
AUTOMATED SCREENING WITH CONFIRMATION OF MECHANISM-BASED INACTIVATION OF CYP3A4, CYP2C9, CYP2C19, CYP2D6, AND CYP1A2 IN POOLED HUMAN LIVER MICROSOMES
Drug Metab. Dispos., August 1, 2005; 33(8): 1211 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
U. S. Justesen, N. A. Klitgaard, K. Brosen, and C. Pedersen
Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers
J. Antimicrob. Chemother., July 1, 2004; 54(1): 206 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Hanioka, S. Ozawa, H. Jinno, T. Tanaka-Kagawa, T. Nishimura, M. Ando, and J.-i. Sawada
Interaction of Irinotecan (CPT-11) and Its Active Metabolite 7-Ethyl-10-Hydroxycamptothecin (SN-38) with Human Cytochrome P450 Enzymes
Drug Metab. Dispos., April 1, 2002; 30(4): 391 - 396.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. M. Hesse, L. L. von Moltke, R. I. Shader, and D. J. Greenblatt
Ritonavir, Efavirenz, and Nelfinavir Inhibit CYP2B6 Activity in Vitro: Potential Drug Interactions with Bupropion
Drug Metab. Dispos., February 1, 2001; 29(2): 100 - 102.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
R. L. Voorman, N. A. Payne, L. C. Wienkers, M. J. Hauer, and P. E. Sanders
Interaction of Delavirdine with Human Liver Microsomal Cytochrome P450: Inhibition of CYP2C9, CYP2C19, and CYP2D6
Drug Metab. Dispos., January 1, 2001; 29(1): 41 - 47.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. R. Jones, J. C. Gorski, M. A. Hamman, B. S. Mayhew, S. Rider, and S. D. Hall
Diltiazem Inhibition of Cytochrome P-450 3A Activity Is Due To Metabolite Intermediate Complex Formation
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1116 - 1125.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
M. A. Gibbs, K. L. Kunze, W. N. Howald, and K. E. Thummel
Effect of Inhibitor Depletion on Inhibitory Potency: Tight Binding Inhibition of CYP3A by Clotrimazole
Drug Metab. Dispos., May 1, 1999; 27(5): 596 - 599.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.